Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
Hosted content
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
Hosted content
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 70, Issue 10
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Inflammatory bowel disease
Original research
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Free
Online download statistics by month:
Online download statistics by month: April 2021 to October 2021
Abstract
Full
Pdf
Apr 2021
2770
2755
636
May 2021
5550
5473
1492
Jun 2021
2412
2347
710
Jul 2021
2216
2099
509
Aug 2021
2283
2241
439
Sep 2021
2183
2172
538
Oct 2021
1906
1867
407
Total
19320
18954
4731
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via BSG
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF